<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02199301</url>
  </required_header>
  <id_info>
    <org_study_id>2010-07-210</org_study_id>
    <nct_id>NCT02199301</nct_id>
  </id_info>
  <brief_title>Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      Kidney transplantation (KT) requires a life-long immune suppression (IS). It has been&#xD;
      well-known that long-term IS inevitably causes various complication e.g. infection, toxicity,&#xD;
      diabetes, osteoporosis, avascular necrosis of hip joint, cataract, acne, and malignancies and&#xD;
      so on. Tolerance induction showing graft function without maintenance IS has been considered&#xD;
      as a final solution in the transplantation recipients. Tolerance induction can be achieved in&#xD;
      KT recipients with donor hematopoietic stem cell transplantation (HSCT).&#xD;
&#xD;
      In this study, adult patients (18 and more years of age) with a human leukocyte antigen&#xD;
      (HLA)-haplotype match donor are enrolled. Patients receive preconditioning treatment for HSCT&#xD;
      1week prior to KT. Bone marrow is harvested from donor under general anesthesia at the time&#xD;
      of nephrectomy for transplantation in donor. Donor BM is infused immediate&#xD;
      post-transplantation at intensive care unit (ICU). Immunologic measurements including&#xD;
      microchimerism study and protocol biopsy will be followed at several time points. IS will be&#xD;
      tapered slowly and withdrawn over a period of several months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune Suppression Withdrawal</measure>
    <time_frame>Immune Suppression Withdrawal within 18 months post-transplantation</time_frame>
    <description>Immune suppression will be tapered-off and withdrawn over the period of 6 to 18 months post-transplantation under the monitoring of graft function and immunologic measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft failure</measure>
    <time_frame>At the post-transplantation 18 months</time_frame>
    <description>In this study, immune suppression(IS) will be tapered-off and withdrawn over the period of 6 to 18 months post-transplantation under the monitoring of graft function and immunologic measurements. At the post-transplantation 18 months we evaluate graft failure episode irrespective of IS withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allograft Rejection</measure>
    <time_frame>At the post-transplantation 18 months</time_frame>
    <description>In this study, immune suppression(IS) will be tapered-off and withdrawn over the period of 6 to 18 months post-transplantation under the monitoring of graft function and immunologic measurements. At the post-transplantation 18 months we evaluate allograft rejection episode irrespective of IS withdrawal.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Microchimerism</measure>
    <time_frame>At post-transplantation 1, 2, 3, 4, 8, and 24 wks</time_frame>
    <description>Presence and proportion of microchimerism in recipient's peripheral blood will be measured by microsatellite short tandem repeat.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune Cell Profiling</measure>
    <time_frame>At post-transplantation 1, 2, 4, 8, 12, 24, and 52 weeks</time_frame>
    <description>Changes of proportion or absolute count of immune cells are measured by flowcytometric analysis in recipient's peripheral blood, using cluster of differentiation (CD) marker.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mixed Lymphocyte Reaction</measure>
    <time_frame>At post-transplantation 8, 24, 52 weeks</time_frame>
    <description>Mixed lymphocyte reaction will be done for the evaluation for the donor-specific immune response (Donor vs. 3rd party) in vitro.</description>
  </other_outcome>
  <other_outcome>
    <measure>Protocol Biopsy</measure>
    <time_frame>Post-transplantation 3, 24, and 52 weeks</time_frame>
    <description>Absence or presence of allograft rejection is confirmed by ultrasonography-guided percutaneous biopsy during follow-up and prior to withdrawal of immunosuppressive agent.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>BMTKT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transplantation Conditioning for bone marrow transplantation (BMT) Kidney transplantation and BMT (BMTKT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transplantation Conditioning for BMT</intervention_name>
    <description>Transplantation Conditioning for BMT (POD#-7~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschr√§nkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)</description>
    <arm_group_label>BMTKT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All consenting adult (18 and more years of age) living donor kidney transplant&#xD;
             recipients who have a one haplotype match donor.&#xD;
&#xD;
          2. Patients who have no known contraindication to administration of rabbit anti-thymocyte&#xD;
             globulin (ATG) or radiation.&#xD;
&#xD;
          3. Patients who agree to participate in the study and sign an Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of previous episode of transplantation including kidney&#xD;
&#xD;
          2. Simultaneous multi-visceral transplantation&#xD;
&#xD;
          3. Demonstration of donor specific antibody (DSA) or panel reactive antibody(PRA) greater&#xD;
             than 20%&#xD;
&#xD;
          4. ABO blood type incompatible&#xD;
&#xD;
          5. Previous treatment with rabbit anti-thymocyte globulin or a known allergy to rabbit&#xD;
             proteins.&#xD;
&#xD;
          6. History of malignancy with the exception of non-melanoma skin malignancies.&#xD;
&#xD;
          7. Uncontrolled systemic or concomitant unstable infection&#xD;
&#xD;
          8. Serological evidence of Hepatitis B or Hepatitis C or HIV infection.&#xD;
&#xD;
          9. Severe psychiatric disease&#xD;
&#xD;
         10. Leukopenia (with a white blood cell count &lt; 3000/mm3)&#xD;
&#xD;
         11. Disagreement to participate in the study and sign an Informed Consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sung Joo Kim, MD, PhD</last_name>
    <phone>82-2-3410-3476</phone>
    <email>kmhyj.kim@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jae Berm Park, MD, PhD</last_name>
    <phone>82-2-3410-3647</phone>
    <email>jbparkmd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center, Organ Transplant Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Joo Kim, MD, PhD</last_name>
      <phone>82-2-3410-3476</phone>
      <email>kmhyj.kim@samsung.com</email>
    </contact>
    <contact_backup>
      <last_name>Jae Berm Park, MD, PhD</last_name>
      <phone>82-2-3410-3647</phone>
      <email>jbparkmd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sung Joo Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jae Berm Park, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2014</study_first_posted>
  <last_update_submitted>July 22, 2014</last_update_submitted>
  <last_update_submitted_qc>July 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Tolerance induction</keyword>
  <keyword>Immunosuppression withdrawal</keyword>
  <keyword>Bone marrow transplantation</keyword>
  <keyword>Transplantation conditioning</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>Living donor</keyword>
  <keyword>Haplotype</keyword>
  <keyword>Immune tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

